CLPUB00123
Cinatl J., Gussetis E.S., Cinatl J. Jr., Ebener U., Mainke M., Schwabe D., Doerr H.-W., Kornhuber B., Gerein V.
Differentiation arrest in neuroblastoma cell culture.
J. Cancer Res. Clin. Oncol. 116 Suppl. 1:9-9(1990)

PubMed=8949988; DOI=10.1097/00001813-199609000-00008
Cinatl J. Jr., Cinatl J., Scholz M., Hernaiz Driever P., Henrich D., Kabickova H., Vogel J.-U., Doerr H.-W., Kornhuber B.
Antitumor activity of sodium valproate in cultures of human neuroblastoma cells.
Anticancer Drugs 7:766-773(1996)

PubMed=9201287
Cinatl J. Jr., Hernaiz Driever P., Cinatl J., Ruckert D.G., Gumbel H.O.C., Rabenau H.F., Kornhuber B., Doerr H.-W.
Increased efficacy of aphidicolin killing of human neuroblastoma cells in vitro by encapsulation in liposomes.
Neoplasma 44:91-95(1997)

PubMed=9443419
Cinatl J. Jr., Cinatl J., Vogel J.-U., Kotchetkov R., Hernaiz Driever P., Kabickova H., Kornhuber B., Schwabe D., Doerr H.-W.
Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells.
Cancer Res. 58:367-372(1998)

PubMed=12532417; DOI=10.1002/ijc.10917
Kotchetkov R., Cinatl J., Blaheta R.A., Vogel J.-U., Karaskova J., Squire J.A., Hernaiz Driever P., Klingebiel T., Cinatl J. Jr.
Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model.
Int. J. Cancer 104:36-43(2003)

PubMed=16151587
Bedrnicek J.B., Vicha A., Jarosova M., Holzerova M., Cinatl J. Jr., Michaelis M., Cinatl J., Eckschlager T.
Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.
Neoplasma 52:415-419(2005)

PubMed=17505515; DOI=10.1038/sj.bjc.6603777; PMCID=PMC2359931
Blaheta R.A., Michaelis M., Natsheh I., Hasenberg C., Weich E., Relja B., Jonas D., Doerr H.-W., Cinatl J. Jr.
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.
Br. J. Cancer 96:1699-1706(2007)

PubMed=22170099; DOI=10.1038/cddis.2011.129; PMCID=PMC3252738
Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M., Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F., Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D., Cinatl J. Jr.
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Cell Death Dis. 2:e243.1-e243.8(2011)

PubMed=24466371; DOI=10.1593/tlo.13544; PMCID=PMC3890703
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013)

PubMed=25749379; DOI=10.18632/oncotarget.2889; PMCID=PMC4627332
Michaelis M., Rothweiler F., Loschmann N., Sharifi M., Ghafourian T., Cinatl J. Jr.
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.
Oncotarget 6:17605-17620(2015)